James B. Koprich

Overview

Best Publications

• Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy

  Chee Yeun Chung;James B. Koprich;Hasan Siddiqi;Ole Isacson

  440
  Citations

• Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease

  James B Koprich;Casper Reske-Nielsen;Prabhakar Mithal;Ole Stefan Isacson

  374
  Citations

• The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease

  Philippe Huot;Tom H. Johnston;James B. Koprich;Susan H. Fox

  371
  Citations

• Animal models of α-synucleinopathy for Parkinson disease drug development

  James B. Koprich;Lorraine V. Kalia;Jonathan M. Brotchie

  246
  Citations

• AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease

  Chi Wang Ip;Laura-Christin Klaus;Akua A. Karikari;Naomi P. Visanji

  195
  Citations

• Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease

  James B Koprich;Tom H Johnston;M Gabriela Reyes;Xuan Sun

  178
  Citations

• α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era

  Naomi P. Visanji;Jonathan M. Brotchie;Lorraine V. Kalia;James B. Koprich

  176
  Citations

• Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson’s Disease

  Qing He;Qing He;James B. Koprich;Ying Wang;Wen-bo Yu

  147
  Citations

• Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice

  Unknown

  137
  Citations

• Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

  Chris McKinnon;Mitchell L. De Snoo;Elise Gondard;Clemens Neudorfer

  128
  Citations

• The Toll-Like Receptor-3 Agonist Polyinosinic:Polycytidylic Acid Triggers Nigrostriatal Dopaminergic Degeneration

  Michela Deleidi;Penelope J. Hallett;James B. Koprich;Chee-Yeun Chung

  123
  Citations

• Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.

  James B. Koprich;Tom H. Johnston;Philippe Huot;M. Gabriela Reyes

  115
  Citations

• Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.

  P. Huot;T.H. Johnston;Katie Lewis;J.B. Koprich

  111
  Citations

• Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat model

  Thomas Musacchio;Maike Rebenstorff;Felix Fluri;Jonathan M. Brotchie

  99
  Citations

• Nigrostriatal Dysfunction in Familial Alzheimer's Disease-Linked APPswe/PS1ΔE9 Transgenic Mice

  Sylvia E. Perez;Orly Lazarov;James B. Koprich;Er Yun Chen

  96
  Citations

• The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.

  James B. Koprich;Susan H. Fox;Tom H. Johnston;Allan Goodman

  90
  Citations

• Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats.

  James B. Koprich;Er Yun Chen;Nicholas M. Kanaan;Nicholas G. Campbell

  89
  Citations

• Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat.

  James B Koprich;Nicholas G Campbell;Jack W Lipton

  75
  Citations

• Propagated α-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice.

  Yan Shen;Wen-Bo Yu;Bo Shen;Hui Dong

  69
  Citations

• The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease.

  Simoneide S. Titze-de-Almeida;Cristina Soto-Sánchez;Eduardo Fernandez;James B. Koprich

  67
  Citations

• UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

  Philippe Huot;Tom H. Johnston;Katie D. Lewis;James B. Koprich

  60
  Citations

• A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson’s disease-like pathology in neurons and glia

  Martin Timo Henrich;Fanni Fruzsina Geibl;Bolam Lee;Wei-Hua Chiu

  60
  Citations

• Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF.

  M.E. Emborg;J. Moirano;J. Raschke;V. Bondarenko

  59
  Citations